Ionis Pharmaceuticals (IONS) Profit After Tax (2009 - 2026)

Ionis Pharmaceuticals' Profit After Tax history runs 18 years deep, the most recent figure standing at -$92.5 million for Q1 2026.

• On a quarterly basis, Profit After Tax rose 37.03% year-over-year to -$92.5 million in Q1 2026; TTM through Mar 2026 was -$327.0 million, a 28.61% increase from a year earlier, with the FY2025 full-year figure at -$381.4 million, up 15.97% from the prior year.
• Profit After Tax grew to -$92.5 million in Q1 2026 per IONS's latest filing, from -$229.4 million in the prior quarter.
• Across five years, Profit After Tax topped out at $123.6 million in Q2 2025 and bottomed at -$229.4 million in Q4 2025.
• The 5-year median for Profit After Tax is -$104.3 million (2024), against an average of -$92.0 million.
• Across the five-year window, Profit After Tax tumbled 1026.51% in 2024 and soared 286.45% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$52.4 million in 2022, then jumped by 82.33% to -$9.3 million in 2023, then tumbled by 1026.51% to -$104.3 million in 2024, then tumbled by 119.83% to -$229.4 million in 2025, then jumped by 59.66% to -$92.5 million in 2026.
• Per Business Quant, the three latest IONS Profit After Tax figures stand at -$92.5 million (Q1 2026), -$229.4 million (Q4 2025), and -$128.6 million (Q3 2025).